Physician profile
Thomas E Blom
NPI 1699756981
$3,066.66
in general payments reported to CMS, 2019-2025
21 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $267 · 2021: $337 · 2022: $475 · 2023: $699 · 2024: $613 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $390.62 | 2019-2024 | Cequa |
| Glaukos Corporation | $309.41 | 2019-2025 | Kxl System (Not Refurbished) |
| Sight Sciences, INC. | $290.26 | 2022-2023 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $247.94 | 2022-2024 | Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $247.81 | 2023-2024 | Acuvue |
| Horizon Therapeutics Plc | $180.15 | 2022-2023 | Tepezza |
| Maculogix, INC. | $131.20 | 2020 | |
| Oyster Point Pharma, INC. | $125.00 | 2024 | Tyrvaya |
| Spark Therapeutics, INC. | $121.85 | 2021 | |
| Amgen INC. | $121.85 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.82 | 2019 | |
| Abbvie INC. | $114.30 | 2023 | Durysta |
| Rxsight INC | $96.52 | 2023 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Coopervision INC. | $95.81 | 2019 | |
| Eyevance Pharmaceuticals LLC | $93.47 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lombart Brothers, INC. | $92.71 | 2020 | |
| Optovue, INC. | $92.59 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $80.58 | 2025 | Xdemvy |
| Samsara Vision | $63.90 | 2022 | |
| Alcon Vision LLC | $36.47 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Blom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.